ATE256180T1 - Detektion und behandlung von mutationen in einem gen für einen cd40-liganden - Google Patents
Detektion und behandlung von mutationen in einem gen für einen cd40-ligandenInfo
- Publication number
- ATE256180T1 ATE256180T1 AT94909478T AT94909478T ATE256180T1 AT E256180 T1 ATE256180 T1 AT E256180T1 AT 94909478 T AT94909478 T AT 94909478T AT 94909478 T AT94909478 T AT 94909478T AT E256180 T1 ATE256180 T1 AT E256180T1
- Authority
- AT
- Austria
- Prior art keywords
- mutations
- detection
- treatment
- ligand gene
- gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US925893A | 1993-01-22 | 1993-01-22 | |
| PCT/US1994/000786 WO1994017196A1 (en) | 1993-01-22 | 1994-01-21 | Detection and treatment of mutations in a cd40 ligand gene |
| US08/184,422 US5565321A (en) | 1993-01-22 | 1994-01-21 | Detection of mutations in a CD40 ligand gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE256180T1 true ATE256180T1 (de) | 2003-12-15 |
Family
ID=26679262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94909478T ATE256180T1 (de) | 1993-01-22 | 1994-01-21 | Detektion und behandlung von mutationen in einem gen für einen cd40-liganden |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6106832A (de) |
| EP (1) | EP0679191B1 (de) |
| AT (1) | ATE256180T1 (de) |
| AU (1) | AU677995B2 (de) |
| CA (1) | CA2153806C (de) |
| DE (1) | DE69433399T2 (de) |
| DK (1) | DK0679191T3 (de) |
| ES (1) | ES2211876T3 (de) |
| NZ (1) | NZ262576A (de) |
| PT (1) | PT679191E (de) |
| WO (1) | WO1994017196A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11508262A (ja) * | 1995-06-22 | 1999-07-21 | バイオジェン,インコーポレイテッド | Cd40リガンドのフラグメントの結晶およびその使用 |
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| US6795473B1 (en) * | 1999-06-23 | 2004-09-21 | Lambda Physik Ag | Narrow band excimer laser with a prism-grating as line-narrowing optical element |
| AU6934600A (en) * | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| WO2001079555A2 (en) | 2000-04-14 | 2001-10-25 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| US7786282B2 (en) | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20060109468A1 (en) * | 2004-11-24 | 2006-05-25 | Evans Richard W | Devices, methods, and systems for measuring an optical property of a sample |
| US20060109467A1 (en) * | 2004-11-24 | 2006-05-25 | Evans Richard W | Devices, methods, and systems for measuring an optical property of a sample |
| US11043823B2 (en) * | 2017-04-06 | 2021-06-22 | Tesla, Inc. | System and method for facilitating conditioning and testing of rechargeable battery cells |
| EP3801640A4 (de) | 2018-05-30 | 2022-03-23 | The Regents Of The University Of California | Geneditierung von monogenen erkrankungen bei menschlichen hämatopoietischen stammzellen - korrektur von x-verbundener agammaglobulinämia (xla) |
| EP4069731A4 (de) | 2019-12-03 | 2024-05-29 | Alamar Biosciences, Inc. | Nukleinsäure-gekoppelter immun-sandwich-assay (nulisa) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5106728A (en) * | 1986-07-03 | 1992-04-21 | Childrens Hospital Of Philadelphia | Callier diagnostic method for agammaglobulinemia and carrier screening method for X linked severe combined immunodeficiency |
| KR100283541B1 (ko) * | 1991-10-25 | 2001-03-02 | 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 | 신규 사이토킨 |
| US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
-
1994
- 1994-01-21 AT AT94909478T patent/ATE256180T1/de not_active IP Right Cessation
- 1994-01-21 ES ES94909478T patent/ES2211876T3/es not_active Expired - Lifetime
- 1994-01-21 PT PT94909478T patent/PT679191E/pt unknown
- 1994-01-21 AU AU62313/94A patent/AU677995B2/en not_active Ceased
- 1994-01-21 DE DE69433399T patent/DE69433399T2/de not_active Expired - Fee Related
- 1994-01-21 WO PCT/US1994/000786 patent/WO1994017196A1/en not_active Ceased
- 1994-01-21 EP EP94909478A patent/EP0679191B1/de not_active Expired - Lifetime
- 1994-01-21 DK DK94909478T patent/DK0679191T3/da active
- 1994-01-21 CA CA002153806A patent/CA2153806C/en not_active Expired - Fee Related
- 1994-01-21 NZ NZ262576A patent/NZ262576A/en not_active IP Right Cessation
-
1996
- 1996-01-22 US US08/589,771 patent/US6106832A/en not_active Expired - Lifetime
-
2000
- 2000-04-10 US US09/545,993 patent/US6613320B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2211876T3 (es) | 2004-07-16 |
| EP0679191B1 (de) | 2003-12-10 |
| EP0679191A1 (de) | 1995-11-02 |
| WO1994017196A1 (en) | 1994-08-04 |
| NZ262576A (en) | 1999-09-29 |
| US6613320B1 (en) | 2003-09-02 |
| CA2153806C (en) | 2005-11-08 |
| DE69433399D1 (de) | 2004-01-22 |
| DK0679191T3 (da) | 2004-04-13 |
| US6106832A (en) | 2000-08-22 |
| CA2153806A1 (en) | 1994-08-04 |
| AU677995B2 (en) | 1997-05-15 |
| EP0679191A4 (de) | 1997-05-21 |
| PT679191E (pt) | 2004-04-30 |
| DE69433399T2 (de) | 2004-10-14 |
| AU6231394A (en) | 1994-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69433399D1 (de) | Detektion und behandlung von mutationen in einem gen für einen cd40-liganden | |
| ATE407362T1 (de) | Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen | |
| IL110754A0 (en) | Cell compositions preparation and therapeutic uses | |
| DK85786A (da) | Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf | |
| ATE249215T1 (de) | Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose | |
| DE69328550D1 (de) | Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln | |
| MX9709915A (es) | Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos. | |
| CA2166931A1 (en) | Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon | |
| Furet et al. | Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design | |
| TNSN87004A1 (fr) | Produit alimentaire enrobe | |
| RU94022254A (ru) | Лиганды, содержащие гетероатом, их комплексы с металлами, способ получения, способ лечения и применение в диагностических наборах | |
| HUT71937A (en) | Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells | |
| ATE221125T1 (de) | Klonierte glutaminsäure-decarboxylase | |
| National Institute of Environmental Health Sciences | NIEHS Report on Health Effects from Exposure to Power-line Frequency Electric and Magnetic Fields: Prepared in Response to the 1992 Energy Policy Act (PL 102-486, Section 2118). | |
| DE69813839D1 (de) | Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz | |
| ATE280777T1 (de) | Bradykinin-antagonist peptide mit n- substituierten glycinen | |
| Olden | NIEHS report on health effects from exposure to power-line frequency electric and magnetic fields | |
| EP0871645A4 (de) | Vorrichtung und verfahren zur geteilten behandlung von abwasser | |
| McGrath et al. | Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 Å | |
| EP0639769A3 (de) | Verwendung eines Elektrodensystems mit Messelektrode, Referenzelektrode und Gegenelektrode zur Messung des Wasserstoffperoxidgehaltes. | |
| DE69321780D1 (de) | Gasdiffusionselektrode und diese verwendender elektrochemische Reaktor | |
| DE59508100D1 (de) | Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander | |
| DE69604492D1 (de) | Neue peptide zur verwendung bei behandlung von durch t-zellen vermittelter knorpelzerstörungin autoimmunkrankheiten | |
| PL313257A1 (en) | Novel tripeptides useful in treating immune system and central nervous system | |
| ATE250630T1 (de) | Kristalle von fragmenten von cd40-liganden und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0679191 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |